304 related articles for article (PubMed ID: 34814904)
1. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting MAPK14 showed anti-prolactinoma effect.
Ding QY; Zhang Y; Ma L; Chen YG; Wu JH; Zhang HF; Wang X
BMC Endocr Disord; 2020 Sep; 20(1):138. PubMed ID: 32894113
[TBL] [Abstract][Full Text] [Related]
3. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
Tang C; Zhu J; Yuan F; Yang J; Cai X; Ma C
Mol Neurobiol; 2021 Dec; 58(12):6170-6185. PubMed ID: 34463926
[TBL] [Abstract][Full Text] [Related]
4. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
5. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells.
Kanasaki H; Fukunaga K; Takahashi K; Miyazaki K; Miyamoto E
Biol Reprod; 2000 Jun; 62(6):1486-94. PubMed ID: 10819748
[TBL] [Abstract][Full Text] [Related]
6. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
Li Q; Su Z; Liu J; Cai L; Lu J; Lin S; Xiong Z; Li W; Zheng W; Wu J; Zhuge Q; Wu Z
Mol Cell Endocrinol; 2014 Jan; 382(1):377-384. PubMed ID: 24184771
[TBL] [Abstract][Full Text] [Related]
7. Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.
Cai L; Leng ZG; Guo YH; Lin SJ; Wu ZR; Su ZP; Lu JL; Wei LF; Zhuge QC; Jin K; Wu ZB
Endocrine; 2016 Jun; 52(3):641-51. PubMed ID: 26662185
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor α/prolactin receptor bilateral crosstalk promotes bromocriptine resistance in prolactinomas.
Xiao Z; Yang X; Zhang K; Liu Z; Shao Z; Song C; Wang X; Li Z
Int J Med Sci; 2020; 17(18):3174-3189. PubMed ID: 33173437
[TBL] [Abstract][Full Text] [Related]
10. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
11. TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models.
Zhang Y; Ma L; Dong S; Ding Q; Wang S; Wu Q; Ni P; Zhang H; Chen Y; Wu J; Wang X
Endocr Relat Cancer; 2022 Dec; 29(12):703-716. PubMed ID: 36219868
[TBL] [Abstract][Full Text] [Related]
12. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
13. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Wang F; Gao H; Li C; Bai J; Lu R; Cao L; Wu Y; Hong L; Wu Y; Lan X; Zhang Y
J Neurooncol; 2014 Jan; 116(1):83-8. PubMed ID: 24135847
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs.
Cheng J; Xie W; Chen Y; Sun Y; Gong L; Wang H; Li C; Zhang Y
Drug Resist Updat; 2024 Mar; 73():101056. PubMed ID: 38277755
[TBL] [Abstract][Full Text] [Related]
15. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
Zhu J; Tang C; Cong Z; Yuan F; Cai X; Yang J; Ma C
Endocr Relat Cancer; 2021 Dec; 29(2):33-46. PubMed ID: 34821219
[TBL] [Abstract][Full Text] [Related]
16. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
18. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
19. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
20. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
